Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros











Intervalo de año de publicación
1.
Neuropsychopharmacology ; 48(2): 308-316, 2023 01.
Artículo en Inglés | MEDLINE | ID: mdl-36175551

RESUMEN

Tobacco use is the leading cause of preventable mortality worldwide. Since current smoking cessation aids show only modest efficacy, new interventions are needed. Given the evidence that stress is a potent trigger for smoking, the present randomized clinical trial tested whether stress could augment the effects of a memory updating (retrieval-extinction) intervention. Non-treatment seeking smokers (n = 76) were assigned to one of four conditions composed of either a stressful or non-stressful psychosocial challenge followed by either smoking or neutral cues. Ten minutes after this manipulation, all underwent a 60-minute extinction procedure during which they viewed smoking-related videos and images and manipulated smoking paraphernalia. Compared to participants who were not exposed to the laboratory stressor, the stressor-exposed groups exhibited greater psychophysiological responses during their intervention and greater decreases in cigarette use at two- and six-weeks follow-up independent of smoking cue exposure. Together, these findings suggest that the ability of stress to activate cigarette seeking processes can be exploited to decrease cigarette use. With replication, the stress-based intervention could become a novel strategy for decreasing cigarette use in non-treatment seeking smokers.Clinicaltrials.gov identifier: NCT04843969.


Asunto(s)
Cese del Hábito de Fumar , Productos de Tabaco , Humanos , Fumadores/psicología , Cese del Hábito de Fumar/métodos , Fumar/terapia , Fumar/psicología , No Fumadores
2.
Naunyn Schmiedebergs Arch Pharmacol ; 392(12): 1591-1604, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31367864

RESUMEN

Hepatocellular carcinoma (HCC) is characterized by bad prognosis and is the second most common reason for cancer-linked mortality. Treatment with sorafenib (SRF) alone increases patient survival by only a few months. A causal link has been determined between angiotensin II (Ang-II) and HCC. However, the mechanisms underlying the tumorigenic effects of Ang-II remain to be elucidated. N-Nitrosodiethylamine was utilized to examine the effects of telmisartan (TEL) (15 mg/kg), SRF (30 mg/kg), and a combination of these two agents on HCC mice. Downregulation of NF-кBP65 mRNA expression and inhibition of the phosphorylation-induced activation of both ERK1/2 and NF-кB P65 were implicated in the anti-tumor effects of TEL and SRF. Consequent regression of malignant changes and improvements in liver function associated with reduced levels of AFP, TNF-α, and TGF-ß1 were also confirmed. Anti-proliferative, anti-metastatic, and anti-angiogenic effects of treatment were indicated by reduced hepatic cyclin D1 mRNA expression, reduced MMP-2 levels, and reduced VEGF levels, respectively. TEL, but not SRF, demonstrated agonistic activity for PPARγ receptors, as evidenced by increased PPARγ DNA binding activity, upregulation of CD36, and HO-1 mRNA expression followed by increased liver antioxidant capacity. Both TEL and SRF inhibited TAK1 phosphorylation-induced activation, indicating that TAK1 might act as a central mediator in the interaction between ERK1/2 and NF-кB. TEL, by modulating the ERK1/2, TAK1, and NF-кB signaling axis in the context of PPARγ agonistic activity, exerted anti-tumor effects and increased tumor sensitivity to SRF. Therefore, TEL is an encouraging agent for further clinical trials regarding the management of HCC.


Asunto(s)
Antihipertensivos/uso terapéutico , Antineoplásicos/uso terapéutico , Carcinoma Hepatocelular/tratamiento farmacológico , Neoplasias Hepáticas/tratamiento farmacológico , Telmisartán/uso terapéutico , Animales , Antihipertensivos/farmacología , Antineoplásicos/farmacología , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Proliferación Celular/efectos de los fármacos , Ciclina D1/genética , Dietilnitrosamina , Células Hep G2 , Humanos , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Quinasas Quinasa Quinasa PAM/metabolismo , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Ratones , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , PPAR gamma/metabolismo , Telmisartán/farmacología , Factor de Transcripción ReIA/genética , Factor de Transcripción ReIA/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo
3.
Brain Struct Funct ; 223(1): 63-76, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-28710525

RESUMEN

The anterior thalamic nuclei (ATN) and the intralaminar/lateral thalamic nuclei (ILN/LT) play different roles in memory processes. The ATN are believed to be part of an extended hippocampal system, and the ILN/LT have strong connections with the medial prefrontal cortex. It was shown that the ILN/LT are involved in systems consolidation. However, whether they are necessary for memory retrieval as well remains unclear. We, therefore, used c-Fos immunohistochemistry and reversible inactivations to investigate the role of the ATN and ILN/LT in recent and remote contextual fear memory retrieval in rats. The results confirm a differential role of the ATN and ILN/LT in systems consolidation, showing the involvement of the ATN in recent but not remote memory retrieval. This study also pinpoints which specific nuclei are involved in retrieval: the anterodorsal nucleus for recent memories, and the lateral mediodorsal nucleus for remote memories. Lastly, we also show that the ATN are not involved in reconsolidation. Together, the results suggest that these nuclei provide critical feedback for successful memory retrieval and systems consolidation.


Asunto(s)
Núcleos Talámicos Anteriores/fisiología , Núcleos Talámicos Intralaminares/fisiología , Consolidación de la Memoria/fisiología , 6-Ciano 7-nitroquinoxalina 2,3-diona/farmacología , Animales , Núcleos Talámicos Anteriores/efectos de los fármacos , Condicionamiento Clásico/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Inmunosupresores/farmacología , Núcleos Talámicos Intralaminares/efectos de los fármacos , Masculino , Aprendizaje por Laberinto/efectos de los fármacos , Aprendizaje por Laberinto/fisiología , Consolidación de la Memoria/efectos de los fármacos , Recuerdo Mental/efectos de los fármacos , Proteínas Proto-Oncogénicas c-fos/metabolismo , Ratas , Ratas Sprague-Dawley , Sirolimus/farmacología , Factores de Tiempo
4.
Cell Rep ; 9(5): 1742-1755, 2014 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-25466251

RESUMEN

Fragile X syndrome (FXS) is the leading genetic cause of autism. Mutations in Fmr1 (fragile X mental retardation 1 gene) engender exaggerated translation resulting in dendritic spine dysmorphogenesis, synaptic plasticity alterations, and behavioral deficits in mice, which are reminiscent of FXS phenotypes. Using postmortem brains from FXS patients and Fmr1 knockout mice (Fmr1(-/y)), we show that phosphorylation of the mRNA 5' cap binding protein, eukaryotic initiation factor 4E (eIF4E), is elevated concomitant with increased expression of matrix metalloproteinase 9 (MMP-9) protein. Genetic or pharmacological reduction of eIF4E phosphorylation rescued core behavioral deficits, synaptic plasticity alterations, and dendritic spine morphology defects via reducing exaggerated translation of Mmp9 mRNA in Fmr1(-/y) mice, whereas MMP-9 overexpression produced several FXS-like phenotypes. These results uncover a mechanism of regulation of synaptic function by translational control of Mmp-9 in FXS, which opens the possibility of new treatment avenues for the diverse neurological and psychiatric aspects of FXS.


Asunto(s)
Benzofuranos/farmacología , Factor 4E Eucariótico de Iniciación/fisiología , Síndrome del Cromosoma X Frágil/tratamiento farmacológico , Metaloproteinasa 9 de la Matriz/genética , Biosíntesis de Proteínas/efectos de los fármacos , Adenosina Trifosfatasas/antagonistas & inhibidores , Animales , Trastorno Autístico/enzimología , Benzofuranos/uso terapéutico , Encéfalo/enzimología , Proteínas de Transporte de Catión/antagonistas & inhibidores , Células Cultivadas , ATPasas Transportadoras de Cobre , Espinas Dendríticas/patología , Inducción Enzimática/efectos de los fármacos , Femenino , Síndrome del Cromosoma X Frágil/enzimología , Síndrome del Cromosoma X Frágil/genética , Humanos , Masculino , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones Endogámicos C57BL , Ratones Transgénicos , Fenotipo , Fosforilación , Procesamiento Proteico-Postraduccional , Receptores de Glutamato Metabotrópico/genética , Receptores de Glutamato Metabotrópico/metabolismo
5.
Elife ; 3: e02736, 2014 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-24963141

RESUMEN

Memory retrieval is considered to have roles in memory enhancement. Recently, memory reconsolidation was suggested to reinforce or integrate new information into reactivated memory. Here, we show that reactivated inhibitory avoidance (IA) memory is enhanced through reconsolidation under conditions in which memory extinction is not induced. This memory enhancement is mediated by neurons in the amygdala, hippocampus, and medial prefrontal cortex (mPFC) through the simultaneous activation of calcineurin-induced proteasome-dependent protein degradation and cAMP responsive element binding protein-mediated gene expression. Interestingly, the amygdala is required for memory reconsolidation and enhancement, whereas the hippocampus and mPFC are required for only memory enhancement. Furthermore, memory enhancement triggered by retrieval utilizes distinct mechanisms to strengthen IA memory by additional learning that depends only on the amygdala. Our findings indicate that reconsolidation functions to strengthen the original memory and show the dynamic nature of reactivated memory through protein degradation and gene expression in multiple brain regions.DOI: http://dx.doi.org/10.7554/eLife.02736.001.


Asunto(s)
Miedo/fisiología , Memoria/fisiología , Amígdala del Cerebelo/metabolismo , Animales , Calcineurina/metabolismo , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/genética , Proteína de Unión a Elemento de Respuesta al AMP Cíclico/metabolismo , Expresión Génica , Hipocampo/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Neuronas/metabolismo , Fosforilación , Corteza Prefrontal/metabolismo , Regiones Promotoras Genéticas , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteínas Proto-Oncogénicas c-fos/genética , Proteínas Proto-Oncogénicas c-fos/metabolismo
6.
Philos Trans R Soc Lond B Biol Sci ; 369(1633): 20130141, 2014 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-24298143

RESUMEN

The molecular processes involved in establishing long-term potentiation (LTP) have been characterized well, but the decay of early and late LTP (E-LTP and L-LTP) is poorly understood. We review recent advances in describing the mechanisms involved in maintaining LTP and homeostatic plasticity. We discuss how these phenomena could relate to processes that might underpin the loss of synaptic potentiation over time, and how they might contribute to the forgetting of short-term and long-term memories. We propose that homeostatic downscaling mediates the loss of E-LTP, and that metaplastic parameters determine the decay rate of L-LTP, while both processes require the activity-dependent removal of postsynaptic GluA2-containing AMPA receptors.


Asunto(s)
Endocitosis/fisiología , Homeostasis/fisiología , Potenciación a Largo Plazo/fisiología , Memoria/fisiología , Modelos Neurológicos , Densidad Postsináptica/metabolismo , Receptores AMPA/metabolismo , Humanos , Metaplasia , Densidad Postsináptica/fisiología
7.
Neuron ; 78(2): 298-311, 2013 Apr 24.
Artículo en Inglés | MEDLINE | ID: mdl-23622065

RESUMEN

Control of protein synthesis is critical for synaptic plasticity and memory formation. However, the molecular mechanisms linking neuronal activity to activation of mRNA translation are not fully understood. Here, we report that the translational repressor poly(A)-binding protein (PABP)-interacting protein 2A (PAIP2A), an inhibitor of PABP, is rapidly proteolyzed by calpains in stimulated neurons and following training for contextual memory. Paip2a knockout mice exhibit a lowered threshold for the induction of sustained long-term potentiation and an enhancement of long-term memory after weak training. Translation of CaMKIIα mRNA is enhanced in Paip2a⁻/⁻ slices upon tetanic stimulation and in the hippocampus of Paip2a⁻/⁻ mice following contextual fear learning. We demonstrate that activity-dependent degradation of PAIP2A relieves translational inhibition of memory-related genes through PABP reactivation and conclude that PAIP2A is a pivotal translational regulator of synaptic plasticity and memory.


Asunto(s)
Potenciación a Largo Plazo/genética , Memoria/fisiología , Neuronas/fisiología , Sinapsis/fisiología , Proteínas Supresoras de Tumor/metabolismo , Adenosina Trifosfatasas/farmacología , Animales , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/metabolismo , Calpaína/farmacología , Células Cultivadas , Condicionamiento Psicológico/efectos de los fármacos , Condicionamiento Psicológico/fisiología , Dactinomicina/farmacología , Inhibidores Enzimáticos/farmacología , Miedo/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/genética , Hipocampo/citología , Potenciación a Largo Plazo/efectos de los fármacos , Masculino , Memoria/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , N-Metilaspartato/farmacología , Neuronas/efectos de los fármacos , Oligodesoxirribonucleótidos/farmacología , Proteínas de Unión a Poli(A) , Inhibidores de la Síntesis de la Proteína/farmacología , ARN Mensajero/metabolismo , Proteínas de Unión al ARN , Tiempo de Reacción/efectos de los fármacos , Tiempo de Reacción/genética , Proteínas Represoras , Proteínas Supresoras de Tumor/genética
8.
Nat Neurosci ; 13(5): 630-4, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20383136

RESUMEN

The maintenance of long-term memory in hippocampus, neocortex and amygdala requires the persistent action of the atypical protein kinase C isoform, protein kinase Mzeta (PKMzeta). We found that inactivating PKMzeta in the amygdala impaired fear memory in rats and that the extent of the impairment was positively correlated with a decrease in postsynaptic GluR2. Blocking the GluR2-dependent removal of postsynaptic AMPA receptors abolished the behavioral impairment caused by PKMzeta inhibition and the associated decrease in postsynaptic GluR2 expression, which correlated with performance. Similarly, blocking this pathway for removal of GluR2-containing receptors from postsynaptic sites in amygdala slices prevented the reversal of long-term potentiation caused by inactivating PKMzeta. Similar behavioral results were obtained in the hippocampus for unreinforced recognition memory of object location. Together, these findings indicate that PKMzeta maintains long-term memory by regulating the trafficking of GluR2-containing AMPA receptors, the postsynaptic expression of which directly predicts memory retention.


Asunto(s)
Memoria/fisiología , Proteína Quinasa C/metabolismo , Receptores AMPA/metabolismo , Análisis de Varianza , Animales , Avidina/metabolismo , Conducta Animal/efectos de los fármacos , Biotinilación/métodos , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/fisiología , Corteza Cerebral/ultraestructura , Condicionamiento Psicológico/efectos de los fármacos , Condicionamiento Psicológico/fisiología , Electrochoque/efectos adversos , Miedo/efectos de los fármacos , Reacción Cataléptica de Congelación/efectos de los fármacos , Hipocampo/fisiología , Hipocampo/ultraestructura , Potenciación a Largo Plazo/efectos de los fármacos , Potenciación a Largo Plazo/fisiología , Masculino , Memoria/efectos de los fármacos , Técnicas de Placa-Clamp/métodos , Péptidos/farmacología , Proteína Quinasa C/química , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/genética , Transporte de Proteínas/fisiología , Ratas , Ratas Long-Evans , Ratas Sprague-Dawley , Reconocimiento en Psicología/efectos de los fármacos , Reconocimiento en Psicología/fisiología , Estadísticas no Paramétricas , Fracciones Subcelulares/metabolismo , Transmisión Sináptica/efectos de los fármacos
9.
Nat Neurosci ; 5(9): 837-8, 2002 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-12172550

RESUMEN

A-kinase anchoring proteins (AKAPs) constitute a family of scaffolding proteins that bind the regulatory subunits of protein kinase A (PKA). AKAP binding to PKA regulates the phosphorylation of various proteins, some of which have been implicated in synaptic plasticity and memory consolidation. Here we show that the regulatory subunits of PKA are colocalized with AKAP150 (an AKAP isoform that is expressed in the brain) in the lateral amygdala (LA) and that infusion to the LA of the peptide St-Ht31, which blocks PKA anchoring onto AKAPs, impairs memory consolidation of auditory fear conditioning.


Asunto(s)
Proteínas Adaptadoras Transductoras de Señales , Amígdala del Cerebelo/enzimología , Vías Auditivas/enzimología , Proteínas Portadoras/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Miedo/fisiología , Memoria/fisiología , Neuronas/enzimología , Proteínas de Anclaje a la Quinasa A , Amígdala del Cerebelo/citología , Animales , Vías Auditivas/citología , Percepción Auditiva/fisiología , Unión Competitiva/efectos de los fármacos , Unión Competitiva/fisiología , Compartimento Celular/efectos de los fármacos , Compartimento Celular/fisiología , Condicionamiento Psicológico/fisiología , Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Sustancias Macromoleculares , Antígenos de Histocompatibilidad Menor , Neuronas/citología , Fosforilación , Unión Proteica/fisiología , Isoformas de Proteínas/antagonistas & inhibidores , Isoformas de Proteínas/metabolismo , Proteínas Proto-Oncogénicas/farmacología , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA